A new therapeutic approach to prevent acute insulin-mediated complications in type 2 diabetes Subtitle: The effect of the combination of the GLP-1 Analog Liraglutide and Insulin Levemir vs. Conventional Insulin Therapy [Neuer Therapieansatz zur Verhinderung akuter Komplikationen bei Typ 2 Diabetes: Der Effekteiner Kombination des GLP-1 Analogons Liraglutide mit Insulin Levemir im Vergleich zur konventionellen Insulintherapie]

Trial Profile

A new therapeutic approach to prevent acute insulin-mediated complications in type 2 diabetes Subtitle: The effect of the combination of the GLP-1 Analog Liraglutide and Insulin Levemir vs. Conventional Insulin Therapy [Neuer Therapieansatz zur Verhinderung akuter Komplikationen bei Typ 2 Diabetes: Der Effekteiner Kombination des GLP-1 Analogons Liraglutide mit Insulin Levemir im Vergleich zur konventionellen Insulintherapie]

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2012

At a glance

  • Drugs Insulin detemir (Primary) ; Liraglutide (Primary) ; Insulin aspart
  • Indications Type 2 diabetes mellitus
  • Focus Biomarker; Pharmacodynamics
  • Acronyms GALILEO
  • Most Recent Events

    • 31 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top